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Abstract 
Aims: -Hydroxybutyrate (GHB) is used as a treatment for narcolepsy and alcohol 
withdrawal and as recreational substance. Nevertheless, there are limited data on the 
pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of GHB in humans. 
We characterized the pharmacokinetic profile and exposure-psychotropic effect relationship 
of GHB in humans.  
Methods: Two oral doses of GHB (25 and 35 mg/kg) were administered to 32 healthy male 
subjects (16 for each dose) using a randomized, placebo-controlled, cross-over design. 
Results: Maximal concentrations of GHB were (geometric mean and 95%CI): 218 (176-270) 
nmol/ml and 453 (374-549) nmol/ml for the 25 and 35 mg/kg GHB doses, respectively. The 
elimination half-lives (mean ± SD) were 36 ± 9 and 39 ± 7 min and the AUC∞ values 
(geometric mean and 95%CI) were 15,747 (12,854-19,290) and 40,113 (33,093-48,622) 
nmol∙min/ml for the 20 and 35 mg/kg GHB doses, respectively. Thus, plasma GHB exposure 
(AUC0-∞) rose disproportionally (+40%) with the higher dose. -Hydroxybutyrate produced 
mixed stimulant-sedative effects, with a dose-dependent increase in sedation and dizziness. 
It did not alter heart rate or blood pressure. A close relationship between plasma GHB 
exposure and its psychotropic effects was found, with higher GHB concentrations associated 
with higher subjective stimulation, sedation, and dizziness. No clockwise hysteresis was 
observed in the GHB concentration effect plot over time (i.e., no acute pharmacological 
tolerance). 
Conclusion: Evidence was found of a non-linear dose-exposure relationship (i.e., no dose 
proportionality) at moderate doses of GHB. The effects of GHB on consciousness were 
closely linked to its plasma exposure and exhibited no acute tolerance. 
 
Keywords: GHB, sodium oxybate, liquid ecstasy, pharmacokinetic 
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What is already known about the subject 
 -Hydroxybutyrate (GHB) presents non-linear elimination kinetics at higher doses in 
humans. 
 -Hydroxybutyrate produces mixed stimulant-sedative subjective effects. 
 
What this study adds 
 At moderate doses, GHB exhibited first-order elimination kinetics but a non-linear 
dose-plasma exposure relationship. 
 A close relationship was found between the plasma GHB concentration and 
subjective effects of GHB over time, with no evidence of acute tolerance. 
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Introduction 
-Hydroxybutyrate (GHB) is a GHB and -aminobutyric acid (GABA) receptor agonist 
[1-3] that is used for the treatment of narcolepsy and alcohol withdrawal but also a 
recreational substance [3-6]. Moreover, GHB has been recently proposed as an 
experimental therapeutic for depressive disorders because of its effects on sleep, vigilance, 
and neuroendocrine parameters [7]. 
Several previous small studies investigated the pharmacokinetics of GHB [8-14]. 
These studies provided partly conflicting findings regarding the linearity of the kinetics of 
GHB and mostly did not assess the psychotropic effects of GHB or the relationship between 
plasma GHB exposure and its psychotropic effects. Brenneisen et al. and Brailsford et al. 
both used single doses of GHB (25 mg/kg) in eight and 12 subjects, respectively, without a 
placebo control or assessments of pharmacodynamic effects [10, 13]. Thai et al. 
characterized the pharmacokinetics of a single dose of 50 mg/kg GHB in 16 subjects and 
included a placebo group, but subjective effects were not assessed [14]. The 
aforementioned studies [10, 13, 14] reported first-order kinetics of GHB. In contrast, Palatini 
et al. documented non-linear kinetics of GHB (12.5, 25, and 50 mg/kg) in eight subjects but 
did not include a placebo condition or evaluate dynamic measures [9]. Similar nonlinear 
elimination kinetics and capacity-limited disposition were noted by other studies [15, 16]. 
Abanades et al. assessed both the pharmacokinetic and pharmacodynamics of GHB (40, 50, 
60, and 72 mg/kg) in a total of eight subjects (n = 2-5/dose) using a placebo-controlled 
design and reported dose-dependent and GHB concentration-related mixed sedative-
stimulant effects [11, 12]. Normalized GHB area-under-the-curve (AUC) values were not 
significantly different, except for the 72 mg/kg dose, indicating non-linear kinetics only at 
higher GHB doses [11]. However, the study was too underpowered to draw valid 
conclusions. Therefore, we examined the pharmacokinetics of GHB together with the 
subjective and cardiovascular effects of GHB in a larger sample using two doses of GHB 
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and a placebo condition in 32 healthy male subjects. -Hydroxybutyrate is endogenously 
produced, and the placebo condition also served as a control condition to correct for 
endogenous levels of GHB in plasma. 
The aims of the present study were (1) to characterize the plasma pharmacokinetics of 
GHB using moderate doses of 20 and 35 mg/kg in a large study sample (n = 32), extending 
the previous small studies that used 25, 40, 50, 60, and 72 mg/kg doses of GHB, (2) to use a 
double-blind, placebo-controlled design to correct for endogenous GHB levels and validly 
determine the psychotropic and cardiovascular effects of GHB, and (3) to assess the plasma 
exposure-psychotropic effect relationship for GHB. 
 
Methods 
Subjects and study design 
The effects of oral GHB were assessed in a randomized, double-blind, placebo-
controlled, balanced cross-over study in 32 healthy, non-smoking, male subjects. Sixteen 
subjects, 24 ± 3 years of age (mean ± SD) and weighing 74 ± 8 kg, were administered GHB 
in an oral dose of 20 mg/kg and placebo. Another 16 subjects, 25 ± 5 years of aged and 
weighing 75 ± 9 kg, were administered GHB in a dose of 35 mg/kg and placebo. The range 
of GHB doses that are typically abused is 25-75 mg/kg (~2-6 g) [6, 11]. The study was 
conducted in accordance with the Declaration of Helsinki and approved by the Ethics 
Committee of the Canton of Zurich and Swiss Agency for Therapeutic Products 
(Swissmedic) and registered at ClinicalTrials.gov (NCT02342366). The subjects were 
recruited via online advertisement at the University of Zurich and provided written informed 
consent before participating in the study and were paid for their participation. On the 
experimental days, a peripheral venous catheter for blood sampling was placed at 8:30 AM, 
and GHB (Xyrem® solution in juice) or placebo (salted juice) was given orally at 9:00 AM. 
Each experimental session lasted 225 min, and the inter-session interval was 7 days. The 
subjects had to be fasting during the morning of the experiments. The exclusion criteria were 
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a medical diagnosis, psychiatric disorders, drug dependence, or regular illicit drug use 
(lifetime use of illegal substances > 5 times with the exception of occasional cannabis use) 
as reported previously [17]. In order to ensure drug abstinence on the test days, urine drug 
screening tests were performed using Dimension RXL Max (Siemens, Erlangen, Germany) 
immunoassays. The present study also evaluated the behavioral and endocrine effects of 
GHB for the lower 20 mg/kg dose as reported elsewhere [17]. 
 
Outcome measures 
Pharmacokinetics  
Blood samples (in EDTA-coated tubes) were collected on ice 20 min before and 35, 
60, 100, 135, and 190 min after drug administration. The samples were centrifuged, and 
plasma was stored at 80°C prior to analysis.  
Quantification of GHB in human plasma 
We determined the plasma concentrations of GHB using gas chromatography-mass 
spectrometry as previously reported [17, 18]. GHB (Xyrem®) as analytical standard was 
purchased from UCB Pharma GmbH, Monheim, Germany. GHB-d6 (internal standard) was 
obtained from Sigma-Aldrich, Steinheim, Germany. Standard solutions: Standard solutions 
were prepared in methanol covering a concentration range of 0.001 to 0.5 mg/mL. For 
constructing calibration curves and to evaluate method performance, 10 or 20 µL of standard 
solutions were applied to plasma samples and followed by sample preparation (see below) 
to reach the analytical range of 4.5 to 4500 pg on column. The calibration curve used for the 
analysis of plasma samples was build using 8 calibration points. An aqueous GHB-d6 
solution of 0.2 µg/mL was used as internal standard (900 pg on column). Sample 
preparation and GC-MS analysis: Details about instrumental conditions used for the analysis 
are shown in [17]. The performance of the method was evaluated using external calibrations 
(i.e. spiking calibration solutions (see standard solutions) into plasma and processing as 
stated above (n=6)) and control samples (n=6). The results were analyzed based on the 
peak area ratio between analyte and internal standard. The calibration curves had a 
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correlation coefficient (R2) of 0.9999±0.0001, a slope of 0.0017±0.0002 (CV 12%) and an 
intercept of -0.0156±0.0062. The inter-day variation coefficient (CV) evaluated at 90 and 900 
pg on column (38 and 380 nmol/mL) were 13% and 15%, respectively. Accuracy was 
between 90 and 115% at 90 and 900 pg on column, respectively. The recovery of control 
samples was in the range of 80-100%. The limit of detection (LOD) was 2.5 pg on column (1 
nmol/mL) and the lower limit of quantification (LLOQ) was 4.5 pg on column (2 nmol/mL). 
The specificity of the method was evaluated on blank samples (distilled water) where no 
GHB was found (<LOD). Using our method the endogenous GHB concentrations after 
placebo administration or before GHB administration were below the LLOQ in three subjects 
and therefore set to 0. 
The pharmacokinetic data were analyzed using non-compartmental models 
(WinNonlin 6.4, Pharsight, Mountain View, CA, USA). Prior to analysis, the plasma 
concentrations of GHB after placebo administration (endogenous GHB production) were 
subtracted from the GHB levels after GHB administration for each of the time points and for 
each subject. Maximal plasma concentration (Cmax) and the time to maximal plasma 
concentration (tmax) were obtained directly from the observed concentration-time curves. The 
terminal elimination rate constant (λz) was estimated by log-linear regression after 
semilogarithmic transformation of the data using at least three data points of the terminal 
linear phase of the concentration-time curve, and the terminal elimination half-life (t1/2) was 
calculated using λz and the equation t1/2 = ln2 / λz. 
 
Subjective effects 
For the measurement of acute subjective drug effects, we used four Visual Analogue 
Scales (VASs), ranging from 0-10, to assess general drug effect, sedation, stimulation, and 
dizziness 15 min before and 40, 60, 100, 120, and 180 min after drug administration as 
similarly used by others [11].  
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Vital signs 
Blood pressure and heart rate were repeatedly measured 10 min before and 40, 60, 
100, 135 and 190 min (± 10 min) after drug administration using a Boso Medicus Uno device 
(Jungingen, Germany). Occasionally missing values because of interfering psychometric 
testing were entered as last observations carried forward. 
 
Pharmacokinetic-pharmacodynamic relationship 
To illustrate the pharmacokinetic-pharmacodynamic relationship, the mean subjective 
changes after GHB administration for each time point were plotted against the respective 
plasma concentrations of GHB and graphed as hysteresis curves. The GHB-induced effect 
was determined for each dose as the difference from placebo in the same subject at the 
corresponding time point to control for circadian changes and endogenous GHB production 
(placebo condition). 
 
Statistical analysis 
Statistical analyses were performed using Statistica 12 (StatSoft, Tulsa, OK, USA). 
Repeated subjective and vital sign measures are expressed as peak effects (Emax). Emax 
values were then compared using repeated-measures analysis of variance (ANOVA), with 
drug (placebo vs. GHB) as the within-subjects factor and dose (low dose vs. high dose) as 
the between-subjects factor. A significant main effect of drug indicates a significant 
difference between drug and placebo in the pooled study sample. A significant dose  drug 
interaction indicates a significant difference between the low and high doses (significant 
dose-response). Tukey post hoc tests were based on significant main effects of drug or dose 
 drug interactions. The criterion for significance was p < 0.05. 
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Results 
Pharmacokinetics 
The GHB plasma concentration-time curves for both doses of GHB are shown in Fig. 
1a. The elimination of GHB followed linear kinetics as shown in Fig. 1b. The pharmacokinetic 
parameters for both doses of GHB are shown in Table 1. Tmax and t1/2 values did not differ 
between the two doses. As expected, the 35 mg/kg GHB dose produced significantly higher 
Cmax, AUC190, and AUC∞ values compared with the 20 mg/kg GHB dose (independent t-tests: 
t30 = 5.08, 6.76, and 6.66, respectively, all p < 0.001). Although the 35 mg/kg dose was 1.75-
fold higher than the 20 mg/kg dose, it produced two-fold higher Cmax values and a 2.5-fold 
higher AUC∞ than the 20 mg/kg dose, indicating a non-linear dose-response relationship. 
Statistical comparisons of the dose-normalized AUC∞ values revealed a significant difference 
in exposure to GHB in the two dose groups (t30 = 2.86, p =0.008), which would not be the 
case if the usual linear dose exposure relationship existed. No significant difference in GHB 
Cmax values was found between the two dose groups (t30 = 1.16, p = 0.26). Thus, although 
elimination was relatively linear and no statistically different t1/2 values were observed for 
both doses, greater than expected plasma exposure (AUC∞) following administration of the 
higher dose was found compared with the lower dose (AUC∞ observed compared with AUC∞ 
expected). Plasma levels of GHB after placebo administration (endogenous GHB) were very 
low (typically between the level of detection and quantification, 2-6 nmol/ml) and stable over 
the six time-points (Fig. 1a). GHB Cmax levels after placebo administration were (mean±SD) 
3.8±2.5 nmol/ml (range: 0-8.9) and thus more than 100 times lower than after administration 
of the 35 mg/kg GHB dose.  
 
Subjective effects 
The subjective effects of GHB over time are shown in Fig. 2. Emax values and statistics 
are shown in Table 2. -Hydroxybutyrate produced a significant general subjective drug 
effect and significant sedation, stimulation, and dizziness that lasted 2 h. The higher GHB 
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dose produced significantly greater overall effects, subjective sedation, and dizziness but not 
more stimulation than the lower dose. 
 
Vital signs 
No significant effects of GHB on vital signs were observed (Fig. 3, Table 2). 
 
Pharmacokinetic-pharmacodynamic relationship 
The GHB plasma exposure-effect relationships over time (hysteresis curves) for the 
subjective responses to GHB are shown in Fig. 4. No acute pharmacological tolerance to the 
effects of GHB was observed (i.e., no clockwise hysteresis). Higher concentrations of GHB 
were generally associated with higher subjective effects of GHB (Fig. 4a-d), and maximal 
subjective sedation (Fig. 4b) coincided with maximal plasma levels of GHB 35-60 min after 
drug administration. Maximal stimulation (Fig. 4c) and dizziness (Fig. 4d) occurred at 60 min 
when plasma GHB levels were already declining. This slight counterclockwise hysteresis 
was consistent with the drug distribution. 
 
Discussion 
The present study assessed the pharmacokinetics and pharmacodynamics of two 
acute oral GHB doses using a placebo-controlled study design in a relatively large sample of 
healthy subjects. The study showed first-order elimination for two different moderate doses 
of GHB in healthy subjects, which was consistent with a previous study that similarly used a 
rather low dose (25 mg/kg) [10]. Elimination was rapid, with an elimination half-life of 
approximately 40 min, which was consistent with previous data [10, 11, 13-15]. In contrast, 
other studies found evidence of non-linear elimination kinetics, particularly at higher GHB 
doses (50-60 mg/kg), with slower early elimination and more rapid later elimination and 
convex log-concentration vs. time profiles [9, 16]. The metabolism of GHB has been 
suggested to become saturated if concentrations exceed 25-30 μg/ml (243-291 nmol/ml), 
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thus resulting in zero-order kinetics [16]. In the present study, such higher concentrations 
were observed only at and shortly after Tmax, and the concentration-time curves may also 
reflect continuing absorption and distribution at that time. However, we found that the GHB 
plasma exposure (AUC∞) rose disproportionally with the higher dose compared with the 
lower dose, indicating non-linear dose-exposure, with approximately 40% greater plasma 
exposure at the higher dose than expected and as similarly described previously [9]. In the 
present study, the dose-normalized Cmax and t1/2 values non-significantly increased but were 
17% and 8% greater at the higher dose compared with the lower dose, respectively, 
indicating that the higher plasma exposure to GHB was a result of both disproportionally 
higher Cmax and slower elimination. Similarly, a previous study that evaluated doses of 12.5, 
25, and 50 mg reported significant increases in dose-normalized AUCs and t1/2 [9]. However, 
in contrast to our findings, Tmax values increased and Cmax values decreased with increasing 
doses, suggesting the capacity-limited absorption of GHB [9], an observation that we could 
not confirm. Notably, however, we obtained only a few samples around Tmax because the 
subjects then performed neurocognitive and behavioral tests [17] not allowing for more 
frequent sampling. This is a limitation of the present study and the Cmax and Tmax values 
obtained are therefore not fully reliable.  Altogether, the clinically most relevant finding of the 
present study and a previous study [9] was the evidence of non-linear kinetics already at low 
to moderate doses of GHB in humans. We and all other previous controlled studies that 
used relatively low doses of GHB (25-72 mg/kg) indicate that the rate-limited elimination 
process of GHB likely becomes even more relevant in cases of GHB intoxication at much 
higher doses [16]. -Hydroxybutyrate is metabolized to succinic semialdehyde by GHB 
dehydrogenase [19]. Succinic semialdehyde is then further converted to succinic acid by 
succinic semialdehyde/aldehyde dehydrogenase [20]. The non-linear kinetics of GHB in 
humans is consistent with capacity-limited GHB metabolism by these dehydrogenases, as 
similarly described for ethanol [21, 22], suggesting similar metabolic pathways for GHB and 
ethanol. Ethanol exposure resulted in a 16% higher Cmax and 29% longer t1/2 of GHB, 
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consistent with enhanced bioavailability and reduced clearance caused by ethanol [14], 
which was also observed with the higher GHB dose in the present study. Thus, concomitant 
ethanol use has similar effects on the pharmacokinetics of GHB as an increase in dose, thus 
partially explaining the severe intoxication seen when GHB is used in combination with 
alcohol [4, 6]. Finally, aldehyde dehydrogenase is a polymorphic enzyme that is well known 
to influence the pharmacokinetics and pharmacodynamics of ethanol in humans [21, 22]. 
Similar genetically determined alterations in exposure to GHB and the drug response remain 
to be studied in humans. 
In the present study, we also newly assessed both the psychotropic and 
cardiovascular effects of GHB under placebo-controlled conditions, thereby also determining 
endogenous GHB levels, and described the pharmacokinetic-pharmacodynamic relationship. 
GHB produced weak stimulant effects but also sedation and dizziness that lasted 
approximately 2 h. Notably, sedation and dizziness were dose-dependent, whereas the 
stimulant effects of the higher dose of GHB did not increase compared with the lower dose. 
Dizziness was also reported in other studies that used controlled GHB administration [9, 11, 
12]. A reduction of the level of consciousness and deep coma rather than stimulant effects 
are the consistent hallmarks of GHB intoxication [4, 6, 23, 24]. It was previously reported that 
GHB-induced feelings of euphoria and stimulation were predominant in the first hour, 
followed by sedating effects in the second hour after GHB administration [11, 12]. We did not 
corroborate these results in the present study. Consistent with previous studies in humans 
[10, 11, 14], we found no significant effects of GHB on blood pressure or heart rate. This 
contrasts with the sympathomimetic stimulant effects of GHB in rats [25]. Bradycardia has 
typically been reported in cases of severe GHB intoxication [6]. In the present study, all of 
the subjective pharmacodynamics effects were closely related to plasma concentrations over 
time and exhibited no acute pharmacological tolerance over the time of acute intoxication. In 
contrast, other GABA agonists, such as benzodiazepines, typically show acute tolerance to 
their sedating and psychomotor effects [26-28]. Determining whether the lack of tolerance to 
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GHB is also present with repeated GHB administration, such with the long-term treatment of 
narcolepsy or GHB dependence, will be interesting for future studies.  
Altogether, we observed a non-linear dose-exposure relationship (i.e., no dose 
proportionality) already at moderate doses of GHB. Additionally, the subjective effects of 
GHB on consciousness were closely linked to its plasma exposure and exhibited no acute 
tolerance. 
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Figure 1. Pharmacokinetics of GHB. (A) The data represent the plasma concentrations of 
GHB (mean and SD) after GHB administration at doses of 20 or 35 mg/kg in 16 subjects for 
each dose group. (B) The dashed lines in the semi-log concentration-time plot represent the 
terminal linear elimination rate (z). -Hydroxybutyrate was administered at t = 0 min. 
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Figure 2. Subjective effects of GHB. (A) -Hydroxybutyrate produced significant general 
subjective drug effects and increased VAS scores of (B) sedation, (C) stimulation, and (D) 
dizziness. The higher dose of GHB produced significantly greater sedation and dizziness 
compared with the lower dose. -Hydroxybutyrate or placebo was administered at t = 0 min.  
The data are expressed as mean and SD in 16 subjects per group. 
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Figure 3. Effects of GHB on vital signs. -Hydroxybutyrate had no significant effects on (A) 
heart rate, (B) systolic blood pressure, or (C) diastolic blood pressure. -Hydroxybutyrate or 
placebo was administered at t = 0 min. The data are expressed as mean and SEM in 16 
subjects per group. 
 
  
  Liechti et al.  
 
 
This article is protected by copyright. All rights reserved. 
 
 
Figure 4. Effects of GHB plotted against GHB plasma concentrations (hysteresis curves). 
The values are expressed as the mean and SD in 16 subjects per dose group. Separate 
plots are shown for the two doses of GHB. The time of sampling is noted next to each point 
in minutes after drug administration. Close relationships were observed between the plasma 
levels of GHB and its subjective drug effects. (A-D) Overall, higher concentrations of GHB 
were associated with higher subjective effects of GHB. (B) Maximal subjective sedation 
coincided with maximal plasma levels of GHB 35-60 min after drug administration. A slight 
delay was observed for VAS (C) stimulation and (D) dizziness, in which the maximal 
responses occurred at 60 min when plasma levels were already declining. This slight 
counterclockwise hysteresis was likely attributable to drug distribution to the effect 
compartment. No evidence of acute pharmacological tolerance to the effects of GHB was 
found (i.e., no clockwise hysteresis). 
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Table 1. Pharmacokinetic parameters for GHB in 16 healthy subjects per dose group. 
 
 
Cmax 
(nmol/mL) 
geometric 
mean 
(95%CI) 
Cmax 
(nmol/mL) 
(range) 
tmax 
(min) 
median 
(range) 
t1/2 
(min) 
mean 
± SD 
t1/2 
(min) 
(range) 
AUC0-190 
(nmol·min/mL) 
geometric 
mean (95% 
CI) 
AUC0-∞ 
(nmol·min/mL) 
geometric 
mean 
(95%CI) 
GHB (20 mg/kg) 
218 (176-
270) 97-481 
35 (35-
60) 36±9 25-58 
15,126 
(12,331-
18,555) 
15,747 
(12,854-
19,290) 
GHB (35 mg/kg) 
453 (374-
549)### 219-843 
35 (35-
60) 39±7 28-53 
38,039 
(31,646-
45,723)### 
40,113 
(33,093-
48,622)### 
GHB (35 mg/kg) dose 
normalized to 20 mg/kg 
259 (214-
314) 125-482 
   
21,736 
(18,083-
26,127)## 
22,922 
(18,911-
27,784)## 
 
AUC, area under the plasma concentration-time curve; AUC0-∞, AUC from time zero to infinity; 
AUC0-190, AUC from time 0-190 min; Cmax, maximum observed plasma concentration; t1/2, plasma 
elimination half-life; tmax, time to Cmax. ##for P<0.01 and ###for P<0.001 indicate significant 
differences compared with the 20 mg/kg dose (independent t-test). 
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Table 2. Values and statistics of maximal drug effects (geometric means and 95%CIs) in 16 
subjects per group. 
  
Placebo 1 
GHB (20 
mg/kg) 
Placebo 2 
GHB (35 
mg/kg) 
Main effect of 
Drug 
Drug × Dose 
Interaction  
  
F1,30 P= F1,30 P= 
Subjective effects 
(Visual Analog 
Scale, VAS scores) 
 
        
 
General drug 
effect 
2.7 (1.2-
6.0) 
3.5 (2.6-
4.8)* 
2.0 (1.2-
3.6) 
4.8 (3.7-
6.3) 46.22 <0.001 5.14 <0.05 
 
Sedation 
2.1 (1.0-
4.4) 
2.7 (1.6-
4.5) 
1.2 (0.5-
2.9) 
4.1 (2.7-
6.2)***# 34.39 <0.001 6.45 <0.05 
 
Stimulation 
2.1 (1.0-
4.4) 
2.7 (1.6-
4.5) 
3.3 (1.3-
8.4) 
4.2 (2.9-
6.0)** 85.56 <0.001 1.51 NS 
 
Dizziness 
1.6 (0.9-
2.9) 
3.0 (2.1-
4.5) 
1.2 (0.5-
2.9) 
3.9 (2.7-
5.6)***## 28.63 <0.001 7.06 <0.01 
Vital signs 
         
 
Systolic blood 
pressure (mm 
Hg) 
132 (126-
138) 
140 
(132-
150) 
139 (130-
149) 
146 (136-
157) 3.96 0.06 0.04 NS 
 
Diastolic blood 
pressure (mm 
Hg) 
81 (78-
84) 
84 (77-
90) 87 (81-94) 91 (85-98) 1.73 NS 0.00 NS 
 
Heart rate 
(beats/min) 
65 (59-
73) 
63 (58-
69) 69 (63-77) 66 (59-72) 2.02 NS 0.13 NS 
 
Rate pressure 
product (mg Hg ∙ 
beats/min) 
8484 
(7492-
9427) 
8760 
(7969-
9630) 
9406 
(8411-
10520) 
9144 
(8138-
10275) 0.00 NS 0.38 NS 
Emax values were compared using repeated-measures analysis of variance (ANOVA), with drug 
(placebo vs. GHB) as the within-subjects factor and dose (low dose vs. high dose) as the between-
subjects factor. A significant main effect of drug indicates a significant difference between drug and 
placebo in the pooled study sample. A significant dose x drug interaction indicates a significant 
difference between the low and high doses (significant dose-response). Tukey post hoc tests were 
based on significant main effects of drug or dose x drug interactions. *P<0.05, **P<0.01, ***P<0.001 
indicate a significant difference between GHB and placebo (Tukey post hoc test). #P < 0.05, ##P < 
0.01 indicate a significant difference between the 20 mg/kg and the 35 mg/kg GHB dose (Tukey post 
hoc test). NS indicates not significant. 
